Detecting at-risk individuals within a healthy population is critical for preventing or delaying Alzheimer's disease. Systems biology integration of brain and body metabolism enables peripheral metabolic biomarkers to serve as reporters of brain bioenergetic status. Using clinical metabolic data derived from healthy postmenopausal women in the Early versus Late Intervention Trial with Estradiol (ELITE), we conducted principal components and k-means clustering analyses of 9 biomarkers to define metabolic phenotypes. Metabolic clusters were correlated with cognitive performance and analyzed for change over 5 years. Metabolic biomarkers at baseline generated 3 clusters, representing women with healthy, high blood pressure, and poor metabolic phenotypes. Compared with healthy women, poor metabolic women had significantly lower executive, global and memory cognitive performance. Hormone therapy provided metabolic benefit to women in high blood pressure and poor metabolic phenotypes. This panel of well-established clinical peripheral biomarkers represents an initial step toward developing an affordable, rapidly deployable, and clinically relevant strategy to detect an at-risk phenotype of late-onset Alzheimer's disease.
Introduction
Effective prevention and delay of Alzheimer's disease (AD) will require intervention during the preclinical phase (Carrillo et al., 2013; Sperling et al., 2011; Yao et al., 2011) . Achievement of this goal entails accurate identification of at-risk individuals before clinically symptomatic disease. Successful screening of at-risk populations requires an accurate, rapidly deployable, clinically accessible, and economically feasible biomarker strategy. To achieve these criteria, biomarkers based on peripheral indicators that accurately predict early risk status of the brain would be advantageous. Interrogating the metabolic system through peripheral indicators provides one such strategy, as substantial evidence supports the hypothesis that midlife metabolism affects cognitive health in older age (Cheng et al., 2012; Gottesman et al., 2014; Kenna et al., 2013; Kivipelto et al., 2001; Norton et al., 2014; Rawlings et al., 2014; Roberts et al., 2014; Wharton et al., 2014; Whitmer et al., 2005) .
One strategy to enrich an at-risk population for biomarker development is to focus on individuals with a greater lifetime risk of AD. Women have a 2-fold greater lifetime risk of developing AD, and thus, constitute a target population for which biomarkers for early detection of risk could have substantial public health impact (Alzheimer's Association, 2014) . Although the biological basis for gender differences in AD remains to be established, basic and clinical science indicate that the menopausal transition and decline in estrogen can adversely affect brain and whole-body metabolism Henderson and Brinton, 2010; Rettberg et al., 2014; Yin et al., 2015) .
Based on basic and clinical science, we hypothesized that metabolically based biomarkers would identify individuals at the tipping point for developing an at-risk for Alzheimer's phenotype in a population of healthy postmenopausal women. To test this hypothesis, we conducted a clustering analysis using baseline data from the Early versus Late Intervention Trial with Estradiol (ELITE; Hodis et al., 2015) to identify metabolic phenotypes. We subsequently investigated the association of these phenotypes with cognitive performance and the longitudinal change in both metabolic phenotypes and cognitive performance over 5 years. We further hypothesized that the administration of hormone therapy (HT) would differentially impact both overall metabolism and cognitive performance within women of different metabolic phenotypes.
Methods

The ELITE clinical trial
ELITE was a double-blinded, placeboecontrolled clinical trial randomizing 643 postmenopausal women. It was designed to test the timing hypothesis of postmenopausal HT, such that HT benefits and risks depend on the temporal initiation of HT relative to timesince-menopause, which is in turn related to underlying tissue health (Henderson et al., 2013; Karim et al., 2015) . Women were recruited into 2 cohorts: early menopause (n ¼ 271), defined as within 6 years of menopause, and late menopause (n ¼ 372), defined as 10 or more years postmenopause.
Eligible women were postmenopausal, defined as absence of menses for !6 months or surgical menopause and serum estradiol below 25 pg/mL. Of the women included, 14 were between 6 months and 1 year postmenopausal, and the remainder were all >1 year postmenopausal. Women were excluded if they had clinical signs, symptoms, or personal history of cardiovascular disease; diabetes mellitus (fasting serum glucose !140 mg/dL); uncontrolled hypertension (diastolic blood pressure !110 mmHg); untreated thyroid disease; plasma triglyceride levels >500 mg/dL; serum creatinine >2.0 mg/dL; cirrhosis or liver disease; a life threatening disease with prognosis <5 years; or inability to determine time-since-menopause. Women with a history of deep vein thrombosis, pulmonary embolism, or breast cancer were excluded. Within each postmenopause cohort, women were randomized to receive either HT (17b-estradiol, 1 mg daily) or placebo. Women who had not undergone a hysterectomy also used vaginal 4% progesterone (or placebo) gel for the last 10 days of each month.
The primary trial outcome was rate of change of distal common carotid artery far wall intima-media thickness . A secondary outcome was change in cognitive function (Henderson et al., 2013) . A comprehensive battery of neuropsychological tests was administered before randomization, at about 2.5 years, and at each participant's final study visit, approximately 5 years after randomization. The battery included 14 neuropsychological tests that emphasized standardized tests sensitive to age-associated change in middle-aged and older adults (Henderson et al., 2013) . ELITE was approved by the Institutional Review Board of the University of Southern California. All participants provided written informed consent.
For the longitudinal analysis, the full sample of 643 women was restricted to those completing cognitive testing at baseline and again at either 2.5 years, 5 years, or both (n ¼ 502). Of the 502 women, 216 were in the early menopause and 286 in the late menopause groups.
Clinical and laboratory measurements
At each 6-month clinic visit, 8-hour fasting blood was drawn, and blood pressure was measured. Current medication use was recorded. Samples were prepared and stored at À70 C.
Fasting glucose, b-hydroxybutyrate, and insulin were measured in stored plasma using kits (glucose and b-hydroxybutyrate:
Cayman Chemical, Ann Arbor, MI, USA; insulin: Alpco Diagnostics, Salem, NH, USA), according to each manufacturer's protocol. Fasting total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol levels were measured in fresh plasma using an enzymatic method of the Standardization Program of the National Centers for Disease Control and Prevention as described previously . Low-density lipoprotein (LDL) cholesterol was computed using the Friedewald equation (Friedewald et al., 1972) . Fasting HbA1c was measured in fresh whole blood using Bio-Rad Hemoglobin A1c high performance liquid chromatography.
Statistical analysis
The analysis included 9 metabolic variables: glucose, the homeostatic model assessment score (HOMA; a measure of insulin resistance: [glucose mmol/L Â insulin]/22.5), ketones (b-hydroxybutyrate), HDL cholesterol, LDL cholesterol, triglycerides, HbA1c, and systolic and diastolic blood pressure (SBP, DBP). These biomarkers were selected on the basis of their contribution to metabolic, cardiovascular, and neurologic health. Insulin and total cholesterol were excluded as these were respectively highly correlated with the HOMA score (R 2 ¼ 0.98, p < 0.0001) and LDL cholesterol (R 2 ¼ 0.89, p < 0.0001). All variables were standardized using baseline averages and standard deviations from the entire ELITE sample. A principal components analysis on the 9 standardized variables identified the number of potential clusters that best explained the variance in the dataset. Specifying 3 clusters, a nonhierarchical K-means clustering algorithm was performed; the resulting 3 clusters were descriptively identified based on their means profile. The 3 clusters were compared on demographic factors and metabolic variables using analysis of variance and covariance for continuous variables and c 2 tests for categorical variables.
Three cognitive composite scores (global cognition, executive functions, and verbal memory) were generated from the 14-item test battery. Composite scores were a linear sum of the standardized test scores within each domain, with each standard test score inversely weighted by its correlation with other contributing cognitive tests (Henderson et al., 2013) . The verbal memory composite score was defined a priori by Word List Free Recall (a short version of the California Verbal Learning Test II) immediate and delayed recall, and Paragraph Recall (East Boston Memory Test) immediate and delayed recall (Henderson et al., 2013) . Tests included in the executive functions composite score were Symbol Digit Modalities Test, Trail Making Test part B, Shipley Abstraction Scale, and category fluency (Animal Naming). These tests were determined by a principal components analysis of baseline scores (Henderson et al., 2013) . The composite score for global cognition was similarly calculated as a weighted average, including all tests in the battery. Analysis of covariance was used to test for overall crosssectional differences among metabolic clusters on each cognitive composite and test; covariates included postmenopause cohort (early/late), random intervention assignment, and education.
Measurements of longitudinal change in metabolic biomarkers used measures at 3 time points (baseline, 2.5 years, and end of study at approximately 5 years) to match with cognitive assessment times. Modeling each metabolic biomarker or cognitive composite separately as the longitudinal dependent variable, data were analyzed using mixed effects linear models, testing the effects of baseline metabolic cluster and menopause cohort on metabolic or cognitive change. The regression coefficient for time (years) since randomization estimated the slope of metabolic/cognitive change (in units/ year). In the mixed model, random effects were specified to allow for subject-specific deviations around the average baseline (regression intercept) and slope of change. Interaction terms of metabolic cluster and treatment condition with time tested whether the slopes significantly differed by these variables. All metabolic analyses included menopause cohort and randomized treatment allocation as independent variables; all cognitive analyses additionally included years of education. All statistical tests used an overall 2-sided alpha of 0.05; post hoc pairwise comparisons corrected for multiple comparisons using the TukeyeKramer method. All associations were evaluated for differences by menopause strata; as no significant differences were found, the analyses for early and late menopause women were collapsed within each phenotype.
Results
Baseline metabolic phenotypes and demographics
The 3 clusters (Fig. 1) were descriptively identified based on their mean profile (Table 1 ): healthy metabolic (n ¼ 209, 41.6%), high blood pressure (BP; n ¼ 191, 38.1%), and poor metabolic (n ¼ 102, 20.3%). Reflecting the clustering algorithm, the healthy and poor metabolic phenotypes significantly differed on all metabolic biomarkers (Table 1 ). Healthy and high BP phenotypes significantly differed on all biomarkers except glucose and HbA1c; High BP and poor metabolic significantly differed on all biomarkers except ketones and LDL cholesterol ( Table 1) . Most of the metabolic biomarker means were within a normal range, consistent with recruitment of a healthy population of postmenopausal women. However, the metabolic biomarker means in the poor metabolic group were at the margins of clinically healthy values (Table 1) . Fig. 1 . Cluster development. Women in the healthy metabolic cluster are shown in green. Women in the high blood pressure cluster are shown in red. Women in the poor metabolic cluster are shown in blue. Can1, the first canonical variable: the linear combination of the clustering variables that best explains cluster group differences (i.e., most correlated with the cluster group). Can2, the second canonical variable: the linear combination of clustering variables that is most correlated with the cluster groups but is uncorrelated with Can1. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Demographics and biomarker values (average, standard deviation) for the 3 phenotypes.
Age, years since menopause, and education were compared using ANOVA. Differences between clusters on menopause cohort and race were assessed using c 2 analysis.
Biomarker results were compared using ANOVA and adjusted for random intervention assignment and menopause cohort (early vs. late). The TukeyeKramer method was used to adjust for multiple comparisons. Key: ANOVA, analysis of variance; BP, blood pressure; HOMA, homeostatic model assessment; SD, standard deviation. a Average value is significantly different from the healthy phenotype (p < 0.05). b Average value is significantly different from the high BP phenotype (p < 0.05).
The cluster groups did not significantly differ on age, years since menopause, or postmenopause cohort (early and/or late; Table 1 ). Women in the healthy phenotype had on average 7 more months of education relative to the poor metabolic phenotype (p ¼ 0.045). The race and/or ethnic distribution significantly differed across clusters (p ¼ 0.0014); Caucasian (44%) and Asian (49%) women had a greater likelihood of membership in the healthy metabolic phenotype. African American women had greater likelihood of membership in the high BP phenotype (44%), whereas Hispanic women were most represented in the poor metabolic phenotype (40%).
Baseline cognitive performance
Cognitive test comparisons were initially adjusted for postmenopause cohort (early vs. late menopause) and random intervention assignment. After these adjustments, the phenotypes significantly differed on global cognition (p ¼ 0.020), verbal memory (p ¼ 0.013), and executive functions (p ¼ 0.019). Women in the healthy phenotype performed significantly better than women in the poor metabolic phenotype on global cognition (p ¼ 0.015), verbal memory (p ¼ 0.009), and executive functions (p ¼ 0.015; Fig. 2A ). Women in the healthy versus high BP phenotypes, and women in the high BP versus poor metabolic phenotypes, did not significantly differ on cognitive performance. With additional adjustment for education, cluster groups did not significantly differ on global cognition (p ¼ 0.085) and executive functions (p ¼ 0.089); group differences on verbal memory remained statistically significant (p ¼ 0.037), with verbal memory significantly different between women in the healthy and poor metabolic phenotypes (p ¼ 0.028; Fig. 2B ).
Effect of aging on metabolic biomarkers and cognition
We initially evaluated the impact of aging over the 5-year trial among the women randomized to placebo using mixed effects models. All women showed a significant amount of metabolic change regardless of metabolic phenotype (Table 2A, showing mean [standard error of the mean] estimates of annual change). Three metabolic biomarkers, HbA1c, HDL cholesterol, and LDL cholesterol, showed changes that can be considered predominantly age-related because the magnitude of change was similar regardless of metabolic phenotype. HbA1c values increased significantly in all women over 5 years, which is a known effect of age even in nondiabetic populations (Pani et al., 2008) . In addition, nearly all women had a significant longitudinal increase in HDL cholesterol and decrease in LDL cholesterol.
Aside from the age-related changes that were apparent in all 3 clusters, the clusters significantly differed on changes in the HOMA score (p ¼ 0. With respect to the cognitive composite scores, women in the healthy, high BP, and poor metabolic phenotypes had significant increases in global cognition and verbal memory (all p < 0.05), with no significant change in executive functions (Table 2B ). The increases in global cognition and verbal memory were likely a learning effect as they were seen in all groups. The magnitude of cognitive change did not significantly differ between metabolic phenotypes.
Longitudinal metabolic and cognitive changes among women randomized to HT
In mixed effects models, women in all 3 metabolic phenotypes randomized to HT showed a significant increase in HbA1c and HDL cholesterol and a significant decrease in LDL cholesterol (Table 3A) . Further, all phenotypes showed a significant decrease in ketones. The clusters significantly differed on changes in the HOMA score (p ¼ 0.02), triglycerides (p < 0.0001), SBP (p < 0.0001), and DBP (p < 0.0001). Women in the healthy phenotype showed a significant increase in triglycerides (p < 0.05; The Writing Group for the PEPI Trial, 1995) . Women in the high BP phenotype had a significant decrease in both SBP (p < 0.0001) and DBP (p < 0.0001), similar to those randomized to placebo. Women in the poor metabolic phenotype had a significant longitudinal A general improvement in cognitive performance was also observed in women randomized to HT (Table 3B) . Women in all 3 metabolic phenotypes showed significant increases in global cognition (all p < 0.05), and women in the healthy and high BP phenotypes had a significant increase in verbal memory (both p < 0.05). Again, this can likely be attributed to a learning effect. There was no significant change in executive functions, and the magnitude of cognitive change did not significantly differ between metabolic phenotypes.
Treatment comparisons on longitudinal metabolic and cognitive changes by cluster groups
On mixed effects models, there were no significant cluster by treatment interactions on the longitudinal trajectory of any metabolic biomarker (Table 4B) . A pairwise comparison of placebo and HT within the healthy phenotype indicated that women on HT had a significantly greater increase in triglycerides than women on placebo (p ¼ 0.018; Table 4A ). Within the high BP phenotype, women on HT had a greater decline in the HOMA score (p ¼ 0.017) and LDL cholesterol (p ¼ 0.004), indicating that high BP women randomized to HT experienced a metabolic benefit (Table 4A) . Within the poor metabolic phenotype, women on HT had a greater increase in HDL cholesterol (p ¼ 0.031) and a smaller increase in HbA1c (p ¼ 0.048), indicating that HT was also of metabolic benefit to these women (Table 4A) .
Pairwise comparisons revealed no significant differences in the magnitude of cognitive composite score change between women randomized to placebo and HT within the 3 phenotypes (Table 4A) . There was no significant cluster by treatment interaction on the longitudinal trajectory of any of the cognitive composite scores (Table 4B ).
Metabolic biomarkers and cognition at study end among women randomized to placebo
At the end of the study, significant differences remained between women in the healthy, high BP, and poor metabolic phenotypes on glucose (p < 0.0001), the HOMA score (p < 0.0001), HDL cholesterol (p < 0.0001), triglycerides (p < 0.0001), HbA1c (p < 0.0001), SBP (p < 0.0001), and DBP (p < 0.0001; Table 5A ). Women in the high BP phenotype only remained significantly different from women in the healthy phenotype on 4 biomarkers (HOMA score, HDL cholesterol, SBP, and DBP, all p < 0.05; Table 4A ); women in the poor metabolic phenotype remained significantly different from women in the healthy phenotype on 7 biomarkers (glucose, HOMA score, HDL cholesterol, triglycerides, HbA1c, SBP, and DBP, all p < 0.05; Table 5A ).
Cognitive composite scores did not differ between women in the 3 metabolic phenotypes for global cognition (p ¼ 0.61), verbal memory (p ¼ 0.79), and executive functions (p ¼ 0.29) at the end of the study (Table 5B) .
Metabolic biomarkers and cognition at study end among women randomized to HT
At the end of the study, significant differences remained between women randomized to HT in the healthy, high BP, and poor metabolic phenotypes on glucose (p < 0.0001), the HOMA score (p < 0.0001), HDL cholesterol (p < 0.0001), triglycerides (p < 0.0001), HbA1c (p < 0.0001), SBP (p < 0.0001), and DBP (p ¼ 0.0004; Table 6A ). Women in the high BP phenotype only remained significantly different from women in the healthy phenotype on SBP and DBP (both p < 0.05, Table 6A ), but women in the poor metabolic phenotype remained significantly different from women in the healthy phenotype on 7 biomarkers (glucose, HOMA score, HDL cholesterol, triglycerides, HbA1c, SBP, and DBP, all p < 0.05; Table 6A ).
Cognitive composite scores did not differ between women in the 3 metabolic phenotypes for global cognition (p ¼ 0.50), verbal memory (p ¼ 0.10), and executive functions (p ¼ 0.59) at the end of the study (Table 6B) . A pairwise comparison revealed that verbal memory was slightly but nonsignificantly higher in healthy compared to poor metabolic women randomized to HT at study end (p ¼ 0.067).
Treatment comparisons on metabolic biomarkers and cognitive composite scores at study end
There were no significant cluster by treatment interactions for any metabolic biomarkers at study end (Table 7) . There were also no significant cluster by treatment interactions on the cognitive composite scores at the study end (Table 7 ). An analysis of the individual cognitive tests revealed an interaction effect of treatment by cluster on the Trails-B test (p ¼ 0.041). In the healthy phenotype, women randomized to HT performed the test an average of 6 seconds slower than women randomized to placebo. This was significantly different from high BP (p ¼ 0.037), where women randomized to HT performed the test an average of 9 seconds faster than women randomized to placebo and poor metabolic, (p ¼ 0.035), where women randomized to HT performed the test an average of 15 seconds faster than women randomized to placebo (data not shown).
Discussion
Using a set of 9 clinically accessible biomarkers, we identified metabolically distinct groups of women within a population characterized as healthy (specifically excluding individuals with cardiovascular disease or diabetes). The data indicate wide variability on each biomarker within this study population that was selected for positive health. However, the variability within this population indicated multiple phenotypes: one met criteria for healthy metabolism, whereas two were at the margins of healthy. Evaluating only one indicator of metabolic health would not have provided such a robust identification of phenotypes of risk because even the individuals that fell within the poor metabolic cluster had mean values at the margin of normal. Thus, in the preclinical transition to disease, multiple indicators may have a higher probability of identifying at-risk individuals.
Within the women randomized to placebo, those in the healthy phenotype showed a slight but significant decline in metabolic health over the 5-year trial. However, the metabolic decline was not reflected in cognitive performance. Thus, women in this phenotype provide a representation of low-risk aging. In the high BP Although not statistically significant, women in the healthy and high BP phenotypes trended toward becoming less healthy during the course of the trial, whereas women in the poor metabolic phenotype trended toward becoming healthier (Tables 2 and 3 ). It is possible that women with a poor metabolic phenotype received a greater benefit from the increased awareness of their health and lifestyle derived from participating in the clinical trial relative to healthy or high BP women. However, the poor metabolic women did not reach a state of metabolic health comparable to the healthy women (Table 5) . Further, although individual biomarkers showed fluctuations at each trial visit, the 3 metabolic phenotypes were very stable over the 5-year trial period. These results highlight the power of using a panel of biomarkers: by doing so, we were able to measure overall systemic change rather than focusing on change within one individual biomarker.
In postmenopausal women, diabetes is associated with a longitudinal decline in cognitive function, and previous research has shown that randomization to HT provides some protection against conversion to diabetes (Bonds et al., 2006; Espeland et al., 2011; Margolis et al., 2004) . In the present study, randomization to HT provided the greatest metabolic benefit to women in the poor metabolic phenotype, as these women showed improvements on nearly every biomarker. Although randomization to HT provided no overall cognitive benefit as measured by the cognitive composite scores, the Trails-B test results indicate that HT ameliorated metabolic effects on executive function for women in the high BP and poor metabolic phenotypes. Thus, although HT provided little metabolic or cognitive benefit to women within the healthy metabolic cluster, it provided metabolic benefit to women classified as poor metabolic and some cognitive benefit to women classified as either high BP or poor metabolic.
The study results highlight the association between ethnicity, metabolic status, and disease risk, consistent with previous studies ( . Although the phenotypes were driven solely by metabolic values and derived independently of race, there was a significant difference in the clusters' racial composition. Epidemiologic data indicate that at nearly every age, African Americans and Hispanics have a higher risk of dementia than Caucasians (Barnes and Bennett, 2014; Seshadri et al., 1997) . The impact of ethnicity may be due to several factors, including genetically determined metabolism (Fitten et al., 2014; Kenney et al., 2014) and differences in quality of education (Carvalho et al., 2015) . Ethnicity also plays a more general role in lifestyle factors such as nutrition and exercise habits, which may further impact metabolic phenotype (Sheikh and Sharma, 2014) .
Although the average age at Alzheimer's diagnosis is approximately 75 years (Holmans et al., 2005) , the prodromal and/or preclinical state of disease begins decades before diagnosis , suggesting large populations of people at risk between approximately 55 and 75 years of age. The systems biology approach underlying the development of peripheral-based metabolic biomarkers described herein provides a rapid, clinically deployable strategy to identify persons who may be at risk for later development of cognitive decline and potentially AD. This approach uses well-established clinical indicators of metabolic function that, when combined, provide a strategy for early detection of risk within a population. The strength of this approach is the ability to identify persons who would be considered normal on a single indicator, but who fall at the margin on multiple indicators, indicative of approaching a transition state to abnormal function. The weakness of this approach is the potential for false positives. However, a false positive can be clinically monitored for reversal of an at-risk phenotype. Moreover, this biomarker set could be used to detect the impact of metabolic interventions. Confirmation of the validity of this biomarker set in persons who transition to mild cognitive impairment or early AD is a critical next step.
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